Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
about
Vaccines: from empirical development to rational designM2e-Based Universal Influenza A VaccinesDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadH5N1 vaccines in humansImmunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent ModelPreclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccineEfficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesImproving pandemic H5N1 influenza vaccines by combining different vaccine platforms.Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.Phase 1 study of pandemic H1 DNA vaccine in healthy adultsMarket implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.Cross-protective immunity to influenza A viruses.Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesNovel viral vectored vaccines for the prevention of influenza.Advances in the development of universal influenza vaccines.Virus-like particles as universal influenza vaccinesExperimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesFusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilitiesA recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.Fast vaccine design and development based on correlates of protection (COPs).Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.Clinical applications of DNA vaccines: current progress.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Technologies for enhanced efficacy of DNA vaccines.Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.Traditional and new influenza vaccinesVaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infectionVaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.Present and future of influenza prevention in pediatrics.
P2860
Q21089599-C285BCD9-88AB-4D0B-870D-620FD8158CADQ26783493-237B3DD8-A977-4C77-B3AD-609C39126FB9Q26783897-20ACD994-8323-456C-B1A4-10F55384A4C4Q27000896-55D5B123-46D3-4C62-AE32-EAD2CFDEC289Q27345320-EFB0B925-740D-400B-A0C6-7C6AE04EC65AQ28631811-8F8FB34B-A8A4-47AD-BBB3-0281579B938DQ30204348-C4BCD845-A91D-4325-9F07-16E4D36A9235Q30352121-FD864E05-2A94-4D7E-88D2-43C4954B800BQ30362811-AA25B5A7-55D8-4B61-8302-CCFFC6A1C92FQ30372481-27D7CDC6-E3B6-4689-893D-FBC6B073C5FBQ30373824-C3332563-EEBA-4DA9-8D2F-D02A8E76A46CQ30375380-909857F4-76D4-4F17-85F6-8EDF0D1E0AF9Q30388390-0625C55B-5B38-4D95-B1A0-AF16431102E3Q30392828-BEB41E32-6035-47E7-A2BC-9AFE92771265Q30396399-6B695B8B-0512-4AE0-B2E0-EE4852F9DA20Q30399477-0D3FA877-8B15-4F81-A831-745C8B1E8FD1Q30402307-7E0285FA-773F-46F4-A6BE-A4D52E2DF73BQ30407424-474B13A2-7DE0-4EB3-909A-CC8C8B53CAC4Q30408295-ADCC0505-2DD7-4EA5-89D1-EE912471202BQ30418570-9E38AF1F-A697-4D5E-929B-02C957D6AE1BQ30421502-C05E1A6F-8DE4-4AEA-8988-052FCE906C12Q30421558-271C462F-B0C5-4AE3-9E64-AB22818911B3Q30427591-5D1F3CC6-4489-431F-B1F2-67C456A74303Q31152863-509D0F50-7676-4659-BBD4-A8871006DFF2Q33815195-1C398D1E-82A9-4E8A-87CD-28CAA667EB61Q34291098-C97B74B4-D838-444B-9D19-BB96B5F2887DQ34309830-B174C2C3-7D16-4115-A0AD-F79F9B8C97A0Q35087579-DB673268-0A92-49B7-82EF-3823D3DE981EQ35452312-D8EC1A23-7642-4393-A992-6A067F9C029FQ35600305-CBD845B9-93BC-41F9-B082-CBAB29F97E08Q35664854-DF7311B8-E6F5-4D35-A7C4-ADB02DC1EE81Q35802958-97AAFABD-2DBA-48E1-A1BB-6AA84F61D56AQ36694825-8C07A3DC-1A03-49F9-B638-4A12FAAEDC79Q37035833-742C4E77-71D0-4DC1-A9E8-A74B2543FFDBQ37127506-022A695A-6C12-4B69-97BF-B5CFFB00B1C5Q37530461-B528BF15-2CAC-4006-95DC-491E16BFDC4DQ37611796-AB34A68D-EB27-43CD-82E3-8BDD0951282AQ37813689-7087D88D-C706-4871-80E9-07E13E642A18Q37825824-0021B5F6-0940-4A79-AEE5-4A621C84F0DBQ37848838-8FCC506C-E292-46DB-91E4-B34B043AF090
P2860
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@ast
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@en
type
label
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@ast
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@en
prefLabel
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@ast
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@en
P2093
P1433
P1476
Phase 1 clinical trials of the ...... enza A virus H5 hemagglutinin.
@en
P2093
Alain P Rolland
Alice H Chu
Casey E Dunne
Cindy L Fisher
Denis Rusalov
Ernest R Kitt
Jennifer A Chaplin
Larry R Smith
Luane R Reyes
Martin L Kabongo
P304
P356
10.1016/J.VACCINE.2010.01.029
P407
P577
2010-01-29T00:00:00Z